Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial

Effect of Alirocumab on Mortality After Acute Coronary Syndromes

(2019) Philippe Gabriel Steg et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

The Evolving Future of PCSK9 Inhibitors

(2018) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Trends in lipid profiles and descriptive characteristics of U.S. adults with and without diabetes and cholesterol-lowering medication use—National Health and Nutrition Examination Survey, 2003–2012, United States

(2018) Carla I. Mercado et al.   PLoS One

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials

(2014) Scott L. Charland et al.   PHARMACOTHERAPY

Lipoprotein(a)-cholesterol: A significant component of serum cholesterol

(2011) Kiyoko Kinpara et al.   CLINICA CHIMICA ACTA

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol

(2011) Judith Hsia et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET